Skip to content

Opinion

At ECRM, the focus shifts to Mitch Bowlus

The final goodbyes have been said, the last stories told. Only the memories of Charlie Bowlus linger, the memories of the personality behind the organization that charted new directions, opened new windows, explored new possibilities and developed new ways of doing business.

In uncertain times, pharmacy’s benefits stand out

As the leaders of community pharmacy gather in Boston for the National Association of Chain Drug Stores Pharmacy and Technology Conference, the profession continues to confront a number of unresolved issues that could have a direct bearing on its ability to provide accessible, affordable patient car

PBM merger reshapes playing field for Rx

a deal that, if it passes muster with government regulators, will combine two of the three largest pharmacy benefit management companies to create a dominant player in the sector — raises a host of challenges for community pharmacy operators and others involved

Merck Adherence Estimator demonstrates worth

The Adherence Estimator, a patient segmentation tool developed by researchers at Merck & Co. to help pharmacists and other health care professionals identify and assist individuals prone to medication nonadherence, has proved its worth in a variety of practice settings since its debut last year.

Tom Ryan: An example for others to follow

The Ryan Years” [in the May 23 issue] brought to mind an occasion five years ago when my wife and I, with our children in tow, set off one evening for a welcoming reception at the NACDS Annual Meeting. We were arriving early, but not for professional reasons.

An exceptional Annual Meeting unfolds

for a variety of reasons not connected to the program or the current issues facing the association or the chain drug industry. More ­specifically: • The 2011 NACDS Annual Meeting marks the last